Molecular monitoring of CML patients
|
|
- Oswin Terry
- 6 years ago
- Views:
Transcription
1 EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany
2 Disclosures Research Support: Advisory Boards: Speaker s Bureau: Novartis, Bristol-Myers Squibb, ARIAD Novartis, Bristol-Myers Squibb, ARIAD Novartis, Bristol-Myers Squibb, ARIAD
3 Learning goals after this session you should be able to describe the benefits and limitations of molecular monitoring in CML patients interpret molecular results in terms of prognostic significance discuss the importance of harmonization of technologies according to the International Scale (IS) reasonably use derived techniques in case of resistance or unsatisfying response
4 Molecular Monitoring: What to measure, what to treat? BCR BCR-ABL BCR-ABL Philadelphia Chromosome ABL mrna Transcript Active Protein Quantitative Determination of BCR-ABL Transcripts using quantitative PCR (RQ-PCR) Inhibition of TK by TKI Adapted from Mensink et al. Br J Haematol 1998;102:768.
5 GCT9310 Monitoring Ph+ CML Disease Hematologic response (HR) Measure of blood counts and differentials Cytogenetic response (CyR) Chromosome banding analysis of marrow cell metaphases Molecular response Measurement of BCR-ABL transcript levels relative to a control gene Most sensitive measure of Ph+ CML disease burden Maslak P. ASH Image Bank. Oct Copyright American Society of Hematology Quintás-Cardama A, et al. Leukemia. 2007; 21(11): Reprinted by permission from Macmillan Publishers Ltd: Leukemia. 2007;21: , copyright Maslak P. ASH Image Bank. Dec Copyright American Society of Hematology
6 Monitoring of CML: European LeukemiaNet Recommendations* GCT9310 Hematologic response (HR) Cytogenetic response (CyR) Molecular response (MR) Every 15 days until CHR Month 3 and 6 and every 6 months until CCyR Every 3 months until MMR Every 3 months Every year Every 6 months CHR, complete hematologic response; CCyR, complete cytogenetic response; MMR, major molecular response. *Baccarani M, et al. J Clin Oncol. 2009;27:
7 Correlation Between Response and Disease Burden: Molecular Response Time Baccarani M, et al. J Clin Oncol. 2009;27(35): Radich JP. Blood. 2009;114:
8 Genetics of Chronic Myeloid Leukemia Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 m -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl p210 bcr-abl p230 bcr-abl
9 Multiplex PCR Qualitative PCR before quantitative PCR! Please ensure that you know the transcript type of your patients! Only b3a2 and/or b2a2 transcripts can be compared according to the IS bp ladder b3a2 b2a2 b3a2, b2a2 e1a2 b2a3 bp ladder Cross et al., 1993
10 Molecular Analyses Quantitative Real-Time RT-PCR using LightCyclertechnology according to the International Scale (IS; Hughes et al., Blood 2006). Other housekeeping genes possible most appropriate: ABL, GUS, B2M, BCR Beillard et al., Leukemia 2003
11 Important for prognosis. - Depth of response - Time to achieve response
12 ELN recommendations 2009 on treatment and diagnostics of CML Optimal Response Suboptimal Response Failure Warning Baseline N/A N/A N/A N/A 3 Month CHR + mcyr (Ph+ < 65%) No CyR (Ph+ > 95%) No CHR High Risk CCA/Ph+ 6 Month PCyR (Ph+ < 35%) Less than PCyR (Ph+ > 35%) No CyR (Ph+ > 95%) N/A 12 Month CCyR (Ph+ = 0%) PCyR (Ph+ < 35%) Less than PCyR (Ph+ > 35%) N/A 18 Month MMR Less than MMR Less than CCyR (Ph+ > 0%) Less than MMR Anytime Stable/ Improving MMR Loss of MMR Mutations* Loss CHR Loss CCyR Mutations* CCA/Ph+ Molecular endpoints do not play a major role so far Baccarani M et al. JCO 27:6041 (2009).
13 Equivalence of cytogenetic with molecular endpoints? - CCyR 1% BCR-ABL IS - PCyR 10% BCR-ABL IS
14 New milestones at 6 months
15 Overall survival by CCyR at 6 months MD Anderson Cancer Center Jabbour E et al. Blood 2011;118: by American Society of Hematology
16 Overall survival by CCyR at 6 months German CML-Study IV Hanfstein B, et al. Leukemia Sep;26(9):
17 Overall Survival (OS) BCR-ABL IS at 6 months 1% vs. 1-10% vs. >10% Hanfstein B, et al. Leukemia Sep;26(9):
18 New milestones at 3 months
19 Predictive value of BCR-ABL level at 3 months on Overall Survival: Cut off IS ~10% BCR-ABL/ABL<9.8% OS = 93.3% (n = 211) P <.001 BCR-ABL/ABL>9.8% OS = 56.9% (n = 68) Marin et al. J Clin Oncol Jan 20;30(3):232-8 (adapted)
20 Overall Survival (OS) by BCR-ABL IS at 3 months 10% vs. >10% 10% >10% BCR-ABL IS n 5Y-OS 10% % >10% % p-value <0.001 Hanfstein B, et al. Leukemia Sep;26(9):
21 Overall Survival (OS) by Ph+ at 3 months 35% vs. >35% 35% >35% Ph+ n 5Y-OS 35% % >35% % p-value Hanfstein B, et al. Leukemia Sep;26(9):
22 Patients alive (%) Overall Survival According to BCR-ABL Levels at 3 Months (DASISION Landmark Analysis) 100 dasatinib 100 mg QD 84% had 10% BCR-ABL 100 imatinib 400 mg QD 64% had 10% BCR-ABL BCR-ABL level at 3 months 3-Year OS 1% 95.5% } P=.7342 >1-10% 96.5% } P=.0525 >10% 85.9% 10% vs >10% P= Months Subjects at risk 1% >1-10% >10% BCR-ABL level at 3 months 3-Year OS 1% 100% } P=.3453 >1-10% 95.0% } P=.0110 >10% 87.8% 10% vs >10% P= Months Subjects at risk 1% >1-10% >10% Saglio G, et al. Blood. 2012;120(21):[abstract 1675].
23 % Alive % Alive Overall Survival at 4 Years by BCR-ABL IS Levels at 3 Months (ENESTnd Landmark Analysis) nilotinib 300 mg BID 97.2% 96.5% 86.7% OS rates at 4 years for 10% vs >10% 60 BCR-ABL at 3 months: % vs 86.7%; P = Pat Evt Cen 30 1% >1% 10% >10% Censored observations Time Since Randomization (Months) P =.6348 P =.0219 imatinib 400 mg QD OS rates at 4 years for 10% vs >10% 60 BCR-ABL at 3 months: % vs 83.6%; P < Pat Evt Cen 30 1% >1% 10% >10% Censored observations Time Since Randomization (Months) 100% 95.3% 83.6% P =.0982 P <.0001 Evaluable patients Nilotinib 300 mg BID (N = 258) Imatinib 400 mg QD (N = 264) BCR-ABL at 3 months 1% N=145 >1 10% N=89 >10% N=24 1% N=43 >1 10% N=133 >10% N=88 % of patients 56% 34% 9% 16% 50% 33% Data cut-off: 27Jul2012. Hochhaus A, et al. Blood. 2012;120(21):[abstract 0167].
24 Evolving recommendations of the ELN Optimal Response Suboptimal Response Failure Warning Baseline N/A N/A N/A N/A 3 Month CHR + mcyr (Ph+ < 65%) No CyR (Ph+ > 95%) No CHR High Risk CCA/Ph+ 6 Month PCyR (Ph+ < 35%) Less than PCyR (Ph+ > 35%) No CyR (Ph+ > 95%) N/A 12 Month CCyR (Ph+ = 0%) PCyR (Ph+ < 35%) Less than PCyR (Ph+ > 35%) N/A 18 Month MMR Less than MMR Less than CCyR (Ph+ > 0%) Less than MMR Anytime Stable/ Improving MMR Loss of MMR Mutations* Loss CHR Loss CCyR Mutations* CCA/Ph+ Baccarani M et al. JCO 27:6041 (2009).
25 Evolving recommendations of the ELN Optimal Response 2009* Optimal Response 2013** Baseline 3 Month 6 Month 12 Month N/A CHR + mcyr (Ph+ < 65%) PCyR (Ph+ < 35%) CCyR (Ph+ = 0%) PCyR (Ph+ 35%) and/or 10% BCR-ABL IS CCyR (Ph+ 0%) and/or 1% BCR-ABL IS 0.1% BCR-ABL IS (MMR) 18 Month MMR Anytime Stable/ Improving MMR *Baccarani M et al. JCO 27:6041 (2009) * * Baccarani M et al. Blood 2013 (accepted for publication on 11 June 2013)
26 Standardization - why? Standardized BCR-ABL monitoring has shown to predict for response Hughes et al., NEJM 2003; Hughes et al., Blood 2010 Hanfstein et al., Leukemia 2012; Marin et al., JCO 2012 Molecular endpoints in recent clinical studies Saglio et al., NEJM 2010; Kantarjian et al., NEJM 2010 Huge variety of molecular methods leads to considerable variation of results Noncomparability of results Confusion of doctors and patients Suboptimal treatment decisions
27 The International Scale (IS) - Background Historical (IRIS trial; 2000): The mean BCR-ABL levels of 30 CML patients was defined as 100% in each of the three participating laboratories using BCR as a control. The value corresponding to MMR in each laboratory defined as 0.1% (reduction of 3 log from IRIS baseline, not from pre-treatment levels in the individual patient!)
28 Proposal of international CML experts for the expression of results in 2006 We propose that the value corresponding to a MMR in each laboratory be mathematically converted to: 0.10% Therefore the International Scale will be fixed to an absolute value as defined in the IRIS trial BCR-ABL local x CF local = BCR-ABL IS Hughes et al., Blood 2006
29 BCR-ABL BCR-ABL levels in 64 labs pre and post conversion CV MMR Level 1 Level 2 Level 3 Level 4 Level 1 Level 2 Level 3 Level 4 reference results Müller et al., Leukemia 2009 BCR-ABL L pre conversion BCR-ABL IS post conversion
30 Standardization of BCR-ABL quantification in Europe participating laboratories in 28 countries Iceland Sweden Finland Norway Estonia Portugal Ireland Spain Denmark Netherlands United Kingdom France Belgium Luxembourg Switzerland Germany Czech Rep Poland Slovakia Austria Hungary Slovenia Croatia Italy Latvia Lithuania Bosnia Serbia and Herzegovina. Albania Belarus Romania - Greece Bulgaria Ukraine Moldova Macedonia Montenegro Russia Turkey Countries with a ref lab with validated CF Countries using a ref lab in a different country Countries with a ref lab validation pending Israel
31 BCR-ABL How to standardize for deeper molecular responses? CV MMR MR 4 MR Level 1 Level 2 Level 3 Level 4 Level 1 Level 2 Level 3 Level 4 reference results Müller et al., Leukemia 2009 BCR-ABL L pre conversion BCR-ABL IS post conversion
32 Do we need to qualify for deep molecular responses? Isn t it enough to get a negative PCR result? BCR-ABL negative sample due to bad sample quality / low sensitivity?
33 Importance of reliable measurement of deep molecular responses Expected that more and more patients under first-line treatment with secondgeneration TKIs (Nilotinib, Dasatinib) will achieve deep molecular response Justification for treatment discontinuation
34 In order to safely stop TKI treatment PCR results need to be comparable (aligned to the International Scale, IS) very sensitive (low sensitivity leads to high number of false negatives)
35 Complete molecular response Definition for the ENEST1st trial Disease (detectable or undetectable) below a defined sensitivity level 4 log below standardized IRIS baseline
36 Definitions of Molecular Response Minimum sample quality required 100% [IRIS baseline] MR 4.0 ( 4 log reduction; 0.01% IS ) 10,000 ABL 10% copies 1% MR 4.5 ( 4.5 log reduction; % IS ) 32,000 ABL 0.1% copies [IRIS MMR] 0.01% MR 5.0 ( 5 log reduction; 0.001% IS ) log reduction = reduction from IRIS baseline, not individual pretreatment levels 100, % ABL copies BCR-ABL undetectable International Scale Cross et al. Leukemia. 2012
37 It s all about Sensitivity Improvement of sensitivity main factors: Number of leukocytes to use (10-20 Mio.) Please ensure that your lab provides you with RNA extraction method (Trizol vs kits) ABL values as a measure for sensitivity! cdna synthesis protocol (use 5µg instead of 1µg RNA) Optimize type and amount of RT enzyme No dilution of cdna
38 ELN Recommendations: Mutation Analysis in Case of Failure and Suboptimal Response Baccarani M, et al. J Clin Oncol 2009;27: Time Failure Suboptimal Response Warnings Diagnosis and before changing to other BCR-ABL inhibitors or other therapy 3 mos No CHR no CyR High risk CCA in Ph+ cells 6 mos < CHR No CyR < PCyR 12 mos < PCyR < CCyR < MMR...and experiencing a 5 to 10-fold BCR-ABL increase while losing MMR 18 mos < CCyR < MMR Anytime CCA in Ph+ cells Loss of CHR Loss of CCyR Mutation (IMinsensitive) Loss of MMR Mutation (IMsensitive) Any transcript level CCA in Ph- cells
39 Most relevant BCR-ABL mutations Less sensitive to nilotinib Less sensitive to dasatinib Specific mutations Cortes J, et al. Leukemia 2008;22: le Coutre P, et al. Blood 2008;111: Hughes T, et al. J Clin Oncol 2009;27: Apperley JF, et al. J Clin Oncol 2009;27: Müller MC, et al. Blood 2009;114: Soverini S, et al. Blood 2011;118: Y253H E255K/V F359C/V T315I Q252H V299L T315A F317L Technical sensitivity of Sanger sequencing ~20%
40 Diagnostic requirements for management of TKI failure Check compliance, ask for side effects Blasts/precursors in PB/BM? AP/BC? BM aspiration, clonal cytogenetic evolution? PB/BM: BCR-ABL mutations? Relevant co-medication? (e.g. Medscape App, Interaction checker) Plasma level?
41 Conclusions (1/2) Ask for: transcript type (once per patient) ABL counts (sensitivity) lab is harmonized according to IS? Early deep responses predict for PFS and OS (any TKI), determined by Molecular Monitoring (and/or Cytogenetics) New ELN recommendations take into account molecular milestones for optimal response and failure, e.g. Optimal at 3 months: 10% BCR-ABL IS and/or PCyR (Ph+ 35%) Optimal at 6 months: 1% BCR-ABL IS and/or CCyR (Ph+ 0%) Molecular Monitoring is more sensitive and allows an early detection of potential relapse (or non-compliance) Can be performed using PB instead of BM
42 Conclusions (2/2) New Goal : Achievement of very deep molecular responses (MR 4, MR 5 ) allowing to consider treatment interruptions within clinical trials (STIM, EUROSKI, ENEST Path) Cure? Standardization of molecular methods is the prerequisite for comparability of results and represents a challenge for interested laboratories due to the permanent need to validate their conversion factor and improve sensitivity TKI failure: Disease phase? Blasts/precursors Cytogenetics: additional chromosomal abnormalities BCR-ABL mutation analysis Compliance? Side effects? Comedication/interactions?
43 Thank you!
Chronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationImpact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis Abstract 479 Giles FJ, Rea D, Baccarani M, Cross NCP, Steegmann
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More informationStopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationTreatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France
Treatment free remission in CML: from the concept to practice François-Xavier Mahon Cancer Center Bordeaux Université Bordeaux, France CML is a model 1960 1970 1980 1990 2000 2010 Philadelphia chromosome
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationWhere we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationOverall survival: 1 st line therapy
1 3 Overall survival: 1 st line therapy 2-year OS phase III studies mm Prices per month of oncology medicin Bloomberg Business weekly 26 Feb 2015 Presented By Veena Shankaran at 2016 ASCO Annual Meeting
More informationIS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London
IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London Tell me generals, are we politicians necessary? I have to admit defeat before starting
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationEngagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationCHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It
CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It Jeffrey H Lipton PhD MD Princess Margaret Cancer Centre Professor of Medicine University of Toronto CAGPO Annual Conference St. John
More informationQ1 What age are you?
Q1 What age are you? Answered: 504 Skipped: 0 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 4.56% 23 3.77% 19 4.56% 23 6.15% 31 3.97% 20 6.55% 33 5.95% 30 6.75% 34 6.35% 32 4.37% 22 6.75% 34 5.56%
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationAlcohol-related harm in Europe and the WHO policy response
Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationEuropean Status report on Alcohol and Health
European Status report on Alcohol and Health Dr Lars Moller Regional Advisor a.i. WHO Regional Office for Europe Main killers in the WHO European Region Source: Preventing chronic diseases. A vital investment.
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationHighlighting in the WHO European Region: Summary. No. 21(February 2012)
No. 21(February 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationLEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
More informationMonthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationPARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information
PARALLELISM AND THE LEGITIMACY GAP 1 Appendix A Country Information PARALLELISM AND THE LEGITIMACY GAP 2 Table A.1 Sample size by country 2006 2008 2010 Austria 2405 2255 0 Belgium 1798 1760 1704 Bulgaria
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationGERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
More informationBurden and cost of alcohol, tobacco and illegal drugs globally and in Europe
Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe Jürgen Rehm 1-4 Kevin D. Shield 1,2,3 1) Centre for Addiction and Mental Health, Toronto, Canada 2) University of Toronto, Canada
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationHighlighting in the WHO European Region:
No. 23(April 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationDepartment of Biological Standardisation OMCL Network & Healthcare (DBO)
Department of Biological Standardisation OMCL Network & Healthcare (DBO) Implementation of Pathogen Reduction Technologies for Blood Components for Transfusion: Updated Table 2009-2010 COUNCIL OF EUROPE
More informationHighlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance
No. 17 (September 2011) A monthly publication on vaccine preventable diseases and immunization data and analysis Issue 15, April 2011 Highlighting in the WHO European Region: measles outbreaks rubella
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationImplementation of Management Guidelines
Implementation of Management Guidelines For Chronic Myeloid Leukemia Perspectives in the United States David Rizzieri, MD; and Joseph O. Moore, MD ABSTRACT Clinical practice guidelines are developed to
More informationPatients Perspective on TKI Generics in Haematology
Patients Perspective on TKI Generics in Haematology Šarūnas Narbutas President, POLA Milan, 14 June 2014 Outlook: TKI* Generics in the EU Market FIRST PATENT EXPIRATION EXCLUSIVITY EXPIRATION (EMA) INN
More informationEuropean status report on alcohol and health Leadership, awareness and commitment
European status report on alcohol and health 2014 Leadership, awareness and commitment Leadership, awareness and commitment Background Strong leadership from national and local governments is essential
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationA report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%
% of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected
More informationQ&A and Technical Support Opening Remarks. Opening Remarks. Susan L. Buchanan, MS, PA-C Dana-Farber Cancer Institute
Susan L. Buchanan, MS, PA-C Dana-Farber Cancer Institute Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute August 7, 2015 Moderated by Rose K. Joyce NCCN, Conferences and Meetings Department This
More informationMedia Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences
Media Release Embargoed 00.01 CET Monday 12 th March 2012 Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences Up to 70 percent of
More informationBiology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationInequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
More informationResearch Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
Disease Markers Volume 216, Article ID 7531472, 5 pages http://dx.doi.org/1.1155/216/7531472 Research Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationThe cancer burden in the European Union and the European Region: the current situation and a way forward
The cancer burden in the European Union and the European Region: the current situation and a way forward Presented by Zsuzsanna Jakab WHO Regional Director for Europe Informal Meeting of Health Ministers
More informationThe health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
More informationPatient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
VOLUME 32 NUMBER 5 FEBRUARY 10 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
More informationWHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More information